EFTA01092057Set 9
2013-08-165p2,594w
market shortly
with map3 cellular allogeneic bone graft. which incorporates
Athersys (ATHX - $1.89) MAPC stem cells, under 361 as well. This
opens the question what other cell therapy products ... market shortly with map3 cellular allogeneic bone graft, which
incorporates Athersys MAPC stem cells. We believe that there are several other companies/products
positioned ideally in the cell therapy space that ... they could be considered minimally
processed. RTI is using Athersys' technology to isolate MAPC-based cells from a qualified donor, and to
combine that with bone material taken from
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092057.pdf
EFTA01092027Set 9
2013-10-125p2,524w
soon be in the market with map3 cellular allogeneic bone
graft, which incorporates Athersys' MAPC stem cells, under 361
as well. This opens the question about other cell therapy products ... market shortly with map3 cellular allogeneic bone graft, which
incorporates Athersys' MAPC stem cells. We believe that there are several other companies/products
positioned ideally in the cell therapy space that ... they could be considered minimally
processed. RTI is using Athersys' technology to isolate MAPC-based cells from a qualified donor, and to
combine them with bone material taken from
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092027.pdf
EFTA01092032Set 9
25p12,760w
using mesenchymal precursor cells (MPCs), and Athersys is using
multipotent adult progenitor cells (MAPCs). Both MPCs and MAPCs are isolated from the bone marrow,
while Pluristem uses placental-derived cells ... these trials include Mesoblast's trial
evaluating purified bone marrow cells (MPCs), Athersys' MAPC, Osiris's expanded mesenchymal stem
cells (MSC), and Capricor's cardiosphere-derived stem cells (CDC). These ... colitis.
Progenitor Cells
Donor, universal able to produce Phase II trial for
Athe rsys (MAPC), expanded ex-
Expanded compatibility, millions of doses Stroke. Phase I proof
vivio and highly
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf
EFTA01364229Set 10
2018-02-051p538w
Abuse; Interview
with Rep. Michele Bachmann; Many Happy Alohas,
http//global factiva conVen/du/article asp'MAPC=S8AccessionNorCNLM000020110308e73800001
• The Observer, MEDIA Article,United Kingdom,Headline:How we stayed wedded to the royals
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01364229.pdf